Multi-cancer screening

1. Multi-cancer screening decreases late-stage cancer incidence in silico (9%-13% by round 10).

   In silicoextended annual screening over 10 rounds (projected by 15 calibrated models)

   Expected late-stage reduction under extended screening in the first multicancer screening trial · Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 16 Sep 2026

Late-stage cancer incidence →